Eledon Pharmaceuticals (ELDN) Operating Income (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Operating Income data on file, last reported at -$21.2 million in Q1 2026.

• Quarterly Operating Income fell 17.91% year-over-year to -$21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.9 million (down 6.79% YoY) and the FY2024 annual result came in at -$70.6 million, down 64.13% from the prior year.
• Operating Income declined to -$21.2 million in Q1 2026, from -$19.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$9.3 million in Q2 2022 to a low of -$58.7 million in Q4 2022.
• A 5-year average of -$17.8 million and a median of -$12.8 million in 2023 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income plunged 525.34% — and 2023, when it jumped 82.38%.
• Tracing ELDN's Operating Income over 5 years: stood at -$58.7 million in 2022, then surged by 82.38% to -$10.3 million in 2023, then sank by 138.89% to -$24.7 million in 2024, then grew by 22.78% to -$19.1 million in 2025, then decreased by 11.07% to -$21.2 million in 2026.
• The last three Operating Income figures came in at -$21.2 million (Q1 2026), -$19.1 million (Q3 2025), and -$24.7 million (Q2 2025), per Business Quant data.